2025-12-04 - Analysis Report
Okay, here's a comprehensive analysis of TransMedics Group Inc. (TMDX) based on the data provided:

**1) Return Rate and Comparison:**

*   **TMDX Overview:** TransMedics Group Inc. is a medical technology company pioneering a novel approach to preserve organ quality for transplant.
*   **TMDX Cumulative Return:** 250.93%
*   **S&P 500 (VOO) Cumulative Return:** 75.82%
*   **Divergence:**  186.2 (Relative Divergence: 81.0)

**Analysis:** TMDX has significantly outperformed the S&P 500 by a wide margin. The divergence of 186.2 indicates a substantial difference in cumulative returns. The relative divergence of 81.0 suggests that the current divergence is relatively high compared to its historical range, but not extremely so, so there is room for further upside potential.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD    | Alpha  | Beta | Cap(B) |
|------------|---------|--------|--------|------|--------|
| 2019-2021  | -18.0%  | 83.5%  | -61.0% | -0.0 | 0.7    |
| 2020-2022  | 94.0%   | 83.5%  | 95.0%  | 0.0  | 2.1    |
| 2021-2023  | 65.0%   | 80.5%  | 64.0%  | 0.1  | 2.7    |
| 2022-2024  | 130.0%  | 85.5%  | 109.0% | 0.1  | 2.1    |
| 2023-2025  | 172.0%  | 85.5%  | 107.0% | 0.3  | 4.9    |

*   **CAGR:**  Shows very strong growth in recent periods, with a substantial increase from 2020-2022 onward.
*   **MDD (Maximum Drawdown):**  Consistently high drawdowns suggest significant price volatility and risk.
*   **Alpha:**  Consistently positive and high Alpha values indicate strong outperformance relative to its risk (Beta) and the market return. The company is generating excess returns.
*   **Beta:** Low Beta values (around 0) suggest that the stock price may move independently from the market.
*   **Cap(B):** Indicates market capitalization in billions. The increasing value suggests growth in company size.

**2) Recent Stock Price Fluctuations:**

*   **Current Price:** 142.59
*   **Last Market Data:** Price: 142.56, Previous Close: 141.77, Change: 0.56
*   **5-day SMA:** 144.89
*   **20-day SMA:** 128.67
*   **60-day SMA:** 122.01

**Analysis:** The stock price closed slightly higher than the previous day. The 5-day SMA is above the current price, suggesting a potential short-term pullback or consolidation.  The 20-day and 60-day SMAs are significantly below the current price, indicating a strong upward trend overall.

**3) Indicators and Signals:**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 65.69 (Approaching overbought territory, but not yet extreme)
*   **PPO:** 1.57 (Positive, indicating upward momentum)
*   **Hybrid Signal:** Buy 100% of cash (7 shares - Very Safe - MRI:0.90). Monthly invest 1.2% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01).
*   **Recent (20 days) relative divergence change:** 14.5 (+) 단기상승 (Short-term rise)
*   **Expected Return (%):** 30.0% (Expected excess return compared to S&P 500 if invested long-term)

**Analysis:**  The MRI suggests a high investment recommendation, indicating that current market conditions are favorable for investment, according to this indicator.  The RSI is approaching overbought, but is not extreme. The PPO is positive, suggesting continued upward momentum. The hybrid signal reinforces the buy recommendation with a specific allocation strategy. The 20-day relative divergence change of 14.5% indicates a recent increase in the stock's outperformance. The expected return of 30% is very attractive compared to S&P 500.

**4) Recent News & Significant Events:**

*   **How sustainable is TMDX stock dividend payout:** This headline is potentially concerning, as dividend sustainability is a critical factor for long-term investors. A deeper dive is needed to evaluate the company's financials.
*   **TransMedics (TMDX): Evaluating Valuation After Strong Year-to-Date Share Price Gains:**  This suggests that the market is assessing whether the stock's current price is justified by its fundamentals after a substantial run-up.
*   **Morgan Stanley Raises Price Target for TMDX to $135:** This is a positive signal, indicating confidence from a major financial institution (However, current stock price is above target price).
*   **New York State Common Retirement Fund Sells 2,025,192 Shares of TransMedics Group, Inc.:**  This is a potentially negative sign, as a large institutional investor is reducing its position.
*   **TMDX Stock Falls Despite Q3 Earnings Beat Estimates, Revenues Up Y/Y:** This is a mixed signal. While earnings and revenues were positive, the market reaction was negative, suggesting concerns beyond the headline numbers.
*   **$TMDX stock is up 13% today. Here's what we see in our data.:** This shows very recent positive momentum.

**4-2) Analyst Opinions:**

*   **Consensus:** Buy (Mean: 1.67)
*   **Opinions:** 11 analysts
*   **Target Price:** Avg: $143.00 / High: $170.00 / Low: $114.00

**Analysis:** Analyst consensus is positive, with a "Buy" rating.  The average target price is slightly above the current price. The high target price suggests potential upside, while the low target price indicates downside risk.

**5) Comprehensive Analysis:**

TMDX has demonstrated exceptional performance, significantly outpacing the S&P 500. The company exhibits strong growth (CAGR), substantial excess returns (Alpha), and the news and indicators are a mix of positive and potentially concerning signals.

**Key Observations & Considerations:**

*   **High Volatility:** The high MDD and past stock price fluctuations make it a relatively risky investment.
*   **Mixed Signals:** There is a mix of positive analyst ratings and target prices, combined with concerns regarding dividend sustainability and the New York State Common Retirement Fund selling shares.
*   **Valuation Concerns:** The news regarding evaluating valuation after strong gains is something to consider, and suggests a deeper analysis is needed to determine if the stock price is sustainable.
*   **Positive Momentum:** Strong growth, recent price increase, and high investment recommendation suggests upward potential.

**Overall Recommendation:**

TMDX appears to be a high-growth, high-risk stock. The strong positive momentum, analyst ratings, and promising expected returns suggest there may be significant potential. However, its high volatility, high MDD, slightly approaching overbought RSI territory, and news regarding dividend sustainability and institutional selling should give potential investors caution. Proceed with caution.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.